No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Alpha-L-Iduronidase (also known as IDUA) is an enzyme that is involved in the breakdown of glycosaminoglycans (GAGs). It is a lysosomal enzyme that is responsible for the degradation of GAGs, which are essential components of the extracellular matrix. Deficiencies in this enzyme can lead to a range of diseases, including mucopolysaccharidosis type I (MPS I). Enzyme replacement therapy (ERT) is the primary treatment for MPS I, and Alpha-L-Iduronidase is the enzyme used in this therapy.
The Alpha-L-Iduronidase market is a rapidly growing market, driven by the increasing prevalence of MPS I and the growing demand for ERT. The market is expected to grow at a steady rate in the coming years, driven by the increasing awareness of MPS I and the availability of new treatments.
Some of the major companies in the Alpha-L-Iduronidase market include Sanofi, Shire, Pfizer, and Genzyme. These companies are involved in the development and manufacture of Alpha-L-Iduronidase for the treatment of MPS I. Show Less Read more
